Natalizumab-associated progressive multifocal leukoencephalopathy in Germany

Multiple Sclerosis

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Lancet Neurol.

Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I

doi: 10.1016/

Multiple Sclerosis

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Ann Neurol.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G

doi: 10.1002/ana.25437.

Multiple Sclerosis

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Lancet Neurol.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D

doi: 10.1016/S1474-4422

Further Publications NeurologyFurther Publications Psychiatry

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

N Engl J Med.

Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A

doi: 10.1056/NEJMoa1815039.

Multiple Sclerosis

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

J Neurol Sci.

Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S, Gaissmaier W

doi: 10.1016/j.jns.2017.03.001.

Multiple Sclerosis

Natalizumab in Multiple Sclerosis: Long-Term Management

Int J Mol Sci.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L

doi: 10.3390/ijms18050940.

Aging and Cognitive Functions

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Lancet Neurol.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ

doi: 10.1016/S1474-4422(17)30161-8.

RECOMMENDED

Multiple Sclerosis

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

Mult Scler Relat Disord.

Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR

doi: 10.1016/j.msard.

Multiple Sclerosis

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis

Expert Opin Drug Saf.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L

doi: 10.1080/14740338.

Related content

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

Natalizumab in Multiple Sclerosis: Long-Term Management

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis